CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Opus Genetics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Opus Genetics Inc
8 DAVIS DRIVE, SUITE 220
Phone: (248) 681-9815p:248 681-9815 DURHAM, NC  27709  United States Ticker: IRDIRD
Business Summary
Opus Genetics, Inc., formerly Ocuphire Pharma, Inc., is a clinical-stage ophthalmic biopharmaceutical company. The Company is engaged in developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. Its pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and being evaluated in a Phase I/II open-label, dose-escalation trial, with advancing early data. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
7812 Motion picture and video tape production
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board CamGallagher 54 11/5/2020 11/5/2020
President, Director Benjamin R.Yerxa 58 10/22/2024 10/22/2024
Chief Executive Officer, Director GeorgeMagrath 39 11/1/2023 11/1/2023
9 additional Officers and Directors records available in full report.

Business Names
Business Name
IRD
OCUP
Rexahn Pharmaceuticals Inc.
REXN
RNN

General Information
Number of Employees: 14 (As of 12/31/2023)
Outstanding Shares: 31,568,457 (As of 11/7/2024)
Shareholders: 75
Stock Exchange: NASD
Federal Tax Id: 113516358
Fax Number: (240) 268-5310


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025